Literature DB >> 12884165

Cholera, diarrhea, and oral rehydration therapy: triumph and indictment.

Richard L Guerrant1, Benedito A Carneiro-Filho, Rebecca A Dillingham.   

Abstract

Cholera drove the sanitary revolution in the industrialized world in the 19th century and now is driving the development of oral rehydration therapy (ORT) in the developing world. Despite the long history of cholera, only in the 1960s and 1970s was ORT fully developed. Scientists described this treatment after the discovery of the intact sodium-glucose intestinal cotransport in patients with cholera. This new understanding sparked clinical studies that revealed the ability of ORT to reduce the mortality associated with acute diarrheal disease. Despite the steady reductions in mortality due to acute dehydrating diarrheal diseases achieved by ORT, the costly morbidity due to these diseases remains, the result of a failure to globalize sanitation and to control the developmental impact of diarrheal diseases and their associated malnutrition. New advances in oral rehydration and nutrition therapy and new methods to recognize its costs are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884165     DOI: 10.1086/376619

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model.

Authors:  Faping Duan; John C March
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  "Cholera forcing". The myth of the good epidemic and the coming of good water.

Authors:  Christopher Hamlin
Journal:  Am J Public Health       Date:  2009-11       Impact factor: 9.308

3.  (p)ppGpp, a Small Nucleotide Regulator, Directs the Metabolic Fate of Glucose in Vibrio cholerae.

Authors:  Young Taek Oh; Kang-Mu Lee; Wasimul Bari; David M Raskin; Sang Sun Yoon
Journal:  J Biol Chem       Date:  2015-04-16       Impact factor: 5.157

4.  2,3-butanediol synthesis and the emergence of the Vibrio cholerae El Tor biotype.

Authors:  Sang Sun Yoon; John J Mekalanos
Journal:  Infect Immun       Date:  2006-10-02       Impact factor: 3.441

5.  Suppressed induction of proinflammatory cytokines by a unique metabolite produced by Vibrio cholerae O1 El Tor biotype in cultured host cells.

Authors:  Wasimul Bari; Yoon-Jae Song; Sang Sun Yoon
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

Review 6.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

7.  Selective suppression by the medical establishment of unwelcome research findings: the cholera treatment evaluation by the General Board of Health, London 1854.

Authors:  Michael Emmans Dean
Journal:  J R Soc Med       Date:  2016-05       Impact factor: 5.344

8.  Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer.

Authors:  Muthusamy Thangaraju; Gail Cresci; Shiro Itagaki; John Mellinger; Darren D Browning; Franklin G Berger; Puttur D Prasad; Vadivel Ganapathy
Journal:  J Gastrointest Surg       Date:  2008-07-26       Impact factor: 3.452

Review 9.  Gastroenterology in developing countries: issues and advances.

Authors:  Kate L Mandeville; Justus Krabshuis; Nimzing Gwamzhi Ladep; Chris J J Mulder; Eamonn M M Quigley; Shahid A Khan
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

10.  Massive fluid requirements and an unusual BUN/creatinine ratio for pre-renal failure in patients with cholera.

Authors:  Muhammad Tariq; Murtaza Memon; Asif Jafferani; Sana Shoukat; Saqib Ali Gowani; Rabeeya Nusrat; Mehmood Riaz; Junaid Patel; Bushra Jamil; Raymond A Smego
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.